LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension

Photo by 19h from unsplash

COPYRIGHT © 2022 Forzano, Mone, Varzideh, Jankauskas, Kansakar, De Luca and Santulli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The… Click to show full abstract

COPYRIGHT © 2022 Forzano, Mone, Varzideh, Jankauskas, Kansakar, De Luca and Santulli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. TYPE Opinion PUBLISHED 09 December 2022 DOI 10.3389/fendo.2022.1097968

Keywords: aldosterone synthase; baxdrostat significantly; selective aldosterone; inhibitor baxdrostat; significantly lowers; synthase inhibitor

Journal Title: Frontiers in Endocrinology
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.